The Company has received approval to list its common shares on the Nasdaq Capital Market under the symbol “ACOG” and is ...

Clene met with the U.S. Food and Drug Administration (FDA) on November 1, 2024, in a Type C meeting to discuss the potential for an accelerated approval pathway in ALS ... and the Company’s existing ...

Change of the Company’s corporate name to Grace Therapeutics, Inc. The Company’s common stock commenced trading under the trading symbol “GRCE” on Nasdaq ... (A-T), for which there are currently no ...

The FDA has granted Jan123 Orphan ... and its Nasdaq ticker symbol was updated to ALTS. On August 26, 2024, the Company appointed Peter Tassiopoulos as CEO. In October, the Board approved the ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

That approval pathway is for devices that are similar to products that are already approved for market. GE HealthCare said the system would offer new capabilities in clinical imaging and neuroscience ...

Autolus Therapeutics ( (AUTL) ) has provided an announcement. Autolus Therapeutics has achieved a pivotal milestone with the FDA’s ...

U.S. FDA approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025 Tot ...

With FDA approval of an investigational device exemption, J&J’s soft tissue robot moves a step closer to challenging ...

Our crowning achievement was the approval and launch of MIPLYFFA, the first FDA-approved therapy for the treatment of Niemann-Pick disease Type C or NPC. This accomplishment was an outcome of our ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop ...

Baird Small/Mid Cap Growth portfolio increased +6.9% in 3Q, net of fees, compared to the +7.0% increase in our primary ...